Market capitalization | $11.62m |
Enterprise Value | $-35.62m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.46 |
P/B ratio (TTM) P/B ratio | 0.22 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-32.48m |
Cash position | $52.29m |
EPS (TTM) EPS | $-1.19 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
4 Analysts have issued a Sensei Biotherapeutics Inc forecast:
4 Analysts have issued a Sensei Biotherapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.55 -0.55 |
71%
71%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -32 -32 |
20%
20%
|
Net Profit | -30 -30 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.
Head office | United States |
CEO | John Celebi |
Employees | 27 |
Founded | 1999 |
Website | senseibio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.